Pre-treatment screening for methotrexate
- haemoglobin
- total white cell count
- neutrophil count
- lymphocyte count
- platelet count
- biochemical profile
- hepatitis B/C markers if abnormal LFTs
(Note - non-invasive scoring using a Fibrosis index (FIB-4) followed by an elastography (e.g. Fibroscan) if indicated is recommended for adults with risk factors for liver disease when starting methotrexate, although this should not delay methotrexate initiation.)
Reference
- Bechman K et al. The 2025 British Society for Rheumatology guideline for the prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs. Rheumatology, Volume 65, Issue 2, February 2026
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.